Prognostic Value of C-Met Overexpression in Hepatocellular Carcinoma: a Meta-analysis and Review

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 23

PMID 29163834

Citations 25

Authors

Jung Han Kim

Hyeong Su Kim

Bum Jun Kim

Hyun Joo Jang

Jin Lee

Affiliations

Soon will be listed here.

Abstract

The overexpression of c-Met protein has been detected in hepatocellular carcinoma (HCC). However, its prognostic impact remains uncertain. We performed this meta-analysis to evaluate the prognostic value of c-Met overexpression in patients who underwent curative surgical resection for HCC. A systematic computerized search of the electronic databases was carried out. From 5 studies, 1,408 patients who underwent surgical resection for HCC were included in the meta-analysis. Compared with patients with HCC having low c-Met expression, patients with c-Met-high tumor showed significantly worse relapse-free survival (hazard ratio = 1.26 [95% confidence interval, 1.02-1.56], = 0.03) and overall survival (hazard ratio = 1.16 [95% confidence interval, 1.03-1.31], = 0.01). In conclusion, our meta-analysis indicates that c-Met overexpression is a significant adverse prognostic factor for recurrence and survival in patients who underwent surgical resection for HCC.

Citing Articles

Identification of basement membrane-related prognostic model associated with the immune microenvironment and synthetic therapy response in pancreatic cancer: integrated bioinformatics analysis and clinical validation.

Zhang B, Chen X, Song H, Gao X, Ma S, Ji H J Cancer. 2024; 15(19):6273-6298.

PMID: 39513120 PMC: 11540510. DOI: 10.7150/jca.100891.

New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: design, synthesis, biological evaluation, and computational studies.

Alamshany Z, Algamdi E, Othman I, Anwar M, Nossier E RSC Adv. 2023; 13(19):12889-12905.

PMID: 37114032 PMC: 10128108. DOI: 10.1039/d3ra01931d.

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.

Ji J, Ha S, Lee D, Sankar K, Koltsova E, Abou-Alfa G Int J Mol Sci. 2023; 24(8).

PMID: 37108802 PMC: 10144688. DOI: 10.3390/ijms24087640.

Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact.

Federico P, Giunta E, Tufo A, Tovoli F, Petrillo A, Daniele B Cancers (Basel). 2022; 14(24).

PMID: 36551730 PMC: 9776845. DOI: 10.3390/cancers14246245.

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.

Rivas S, Marin A, Samtani S, Gonzalez-Feliu E, Armisen R Int J Mol Sci. 2022; 23(22).

PMID: 36430388 PMC: 9697723. DOI: 10.3390/ijms232213898.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Sterne J, Sutton A, Ioannidis J, Terrin N, Jones D, Lau J . Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011; 343:d4002. DOI: 10.1136/bmj.d4002. View

Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem J . Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2012; 14(1):55-63. DOI: 10.1016/S1470-2045(12)70490-4. View

Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S . Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013; 31(32):4067-75. DOI: 10.1200/JCO.2012.45.8372. View

Wang Z, Liang P, Dong B, Yu X, Yu D . Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg. 2007; 12(2):327-37. DOI: 10.1007/s11605-007-0310-0. View

Peters S, Adjei A . MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012; 9(6):314-26. DOI: 10.1038/nrclinonc.2012.71. View

DErrico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C . Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology. 1996; 24(1):60-4. DOI: 10.1002/hep.510240112. View

Yan S, Jiao X, Zou H, Li K . Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. Diagn Pathol. 2015; 10:62. PMC: 4458003. DOI: 10.1186/s13000-015-0296-y. View

Panic N, Leoncini E, De Belvis G, Ricciardi W, Boccia S . Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2014; 8(12):e83138. PMC: 3873291. DOI: 10.1371/journal.pone.0083138. View

10.

Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F . Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(24):2667-74. DOI: 10.1200/JCO.2014.60.7317. View

11.

Nagashima I, Hamada C, Naruse K, Osada T, Nagao T, Kawano N . Surgical resection for small hepatocellular carcinoma. Surgery. 1996; 119(1):40-5. DOI: 10.1016/s0039-6060(96)80211-x. View

12.

Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng D . Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014; 20(11):2959-70. DOI: 10.1158/1078-0432.CCR-13-2620. View

13.

Furukawa T, DUGUID W, Kobari M, Matsuno S, Tsao M . Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol. 1995; 147(4):889-95. PMC: 1870999. View

14.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

15.

Qi X, Guo X, Han G, Li H, Chen J . MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 2015; 21(18):5445-53. PMC: 4427665. DOI: 10.3748/wjg.v21.i18.5445. View

16.

Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T . C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One. 2013; 8(11):e79137. PMC: 3817069. DOI: 10.1371/journal.pone.0079137. View

17.

Chu J, Ge F, Zhang B, Wang Y, Silvestris N, Liu L . Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013; 32:16. PMC: 3623756. DOI: 10.1186/1756-9966-32-16. View

18.

Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M . Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 2012; 18(2):207-13. DOI: 10.1007/s10147-011-0361-9. View

19.

Zhuang P, Xu L, Gao L, Lu W, Ruan L, Yang J . Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma. Onco Targets Ther. 2017; 10:847-857. PMC: 5317332. DOI: 10.2147/OTT.S113353. View

20.

Jung K, Won Y, Oh C, Kong H, Lee D, Lee K . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014. Cancer Res Treat. 2017; 49(2):292-305. PMC: 5398380. DOI: 10.4143/crt.2017.118. View